Vinorelbine and Cisplatin in Patients with Advanced Non-small Cell Lung Cancer with Interstitial Pneumonia

被引：1

作者：

Watanabe, Naohiro ^{[1
]}

Niho, Seiji ^{[1
]}

Kirita, Keisuke ^{[1
]}

Umemura, Shigeki ^{[1
]}

Matsumoto, Shingo ^{[1
]}

Yoh, Kiyotaka ^{[1
]}

Ohmatsu, Hironobu ^{[1
]}

Goto, Koichi ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba 2778577, Japan

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 03期

关键词：

Acute exacerbation; cisplatin; interstitial pneumonia; non-small cell lung cancer; vinorelbine; IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; WEEKLY PACLITAXEL; RISK-FACTORS; DISEASE; EFFICACY; CHEMOTHERAPY; COMBINATION; CARBOPLATIN; SAFETY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). Patients and Methods: A total of 67 patients treated with vinorelbine and cisplatin as a first-line chemotherapy between January 2002 and December 2013 were retrospectively reviewed. Results: The overall response rate was 34.3% [95% confidence interval (CI)=22.9%-45.7%). The median progression-free survival, median overall survival, and I-year survival rates were 3.7 months (95% CI=3.1-4.3 months), 7.4 months (95% CI=5.4-9.4 months), and 22.4% (95% CI=12.4%-32.4%), respectively. The incidence of acute exacerbation of IP following first-line chemotherapy was 10.4%. Conclusion: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis.

引用

页码：1697 / 1701

页数：5

共 27 条

[1] Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].

Azuma, A ;

Nukiwa, T ;

Tsuboi, E ;

Suga, M ;

Abe, S ;

Nakata, K ;

Taguchi, Y ;

Nagai, S ;

Itoh, H ;

Ohi, M ;

Sato, A ;

Kudoh, S ;

Raghu, G .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047

[2] Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease [J].

Choi, Moon Ki ;

Hong, Jung Yong ;

Chang, Wonjin ;

Kim, Moonjin ;

Kim, Sungmin ;

Jung, Hyun Ae ;

Lee, Su Jin ;

Park, Silvia ;

Chung, Man Pyo ;

Sun, Jong-Mu ;

Park, Keunchil ;

Ahn, Myung-Ju ;

Ahn, Jin Seok .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) :1217-1225

[3] Acute exacerbations of idiopathic pulmonary fibrosis [J].

Collard, Harold R. ;

Moore, Bethany B. ;

Flaherty, Kevin R. ;

Brown, Kevin K. ;

Kaner, Robert J. ;

King, Talmadge E., Jr. ;

Lasky, Joseph A. ;

Loyd, James E. ;

Noth, Imre ;

Olman, Mitchell A. ;

Raghu, Ganesh ;

Roman, Jesse ;

Ryu, Jay H. ;

Zisman, David A. ;

Hunninghake, Gary W. ;

Colby, Thomas V. ;

Egan, Jim J. ;

Hansell, David M. ;

Johkoh, Takeshi ;

Kaminski, Naftali ;

Kim, Dong Soon ;

Kondoh, Yasuhiro ;

Lynch, David A. ;

Mueller-Quernheim, Joachim ;

Myers, Jeffrey L. ;

Nicholson, Andrew G. ;

Selman, Moises ;

Toews, Galen B. ;

Wells, Athol U. ;

Martinez, Fernando J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (07) :636-643

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Cryptogenic fibrosing alveolitis and lung cancer: the BTS study [J].

Harris, J. M. ;

Johnston, I. D. A. ;

Rudd, R. ;

Taylor, A. J. Newman ;

Cullinan, P. .

THORAX, 2010, 65 (01) :70-76

[6] Lung cancer and cryptogenic fibrosing alveolitis - A population-based cohort study [J].

Hubbard, R ;

Venn, A ;

Lewis, S ;

Britton, J .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (01) :5-8

[7] Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy [J].

Isobe, Kazutoshi ;

Hata, Yoshinobu ;

Sakamoto, Susumu ;

Takai, Yujiro ;

Shibuya, Kazutoshi ;

Homma, Sakae .

RESPIROLOGY, 2010, 15 (01) :88-92

[8] The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer [J].

Kenmotsu, Hirotsugu ;

Naito, Tateaki ;

Kimura, Madoka ;

Ono, Akira ;

Shukuya, Takehito ;

Nakamura, Yukiko ;

Tsuya, Asuka ;

Kaira, Kyoichi ;

Murakami, Haruyasu ;

Takahashi, Toshiaki ;

Endo, Masahiro ;

Yamamoto, Nobuyuki .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) :1242-1246

[9]

Kondoh Y, 2010, SARCOIDOSIS VASC DIF, V27, P103

[10] ACUTE EXACERBATION IN IDIOPATHIC PULMONARY FIBROSIS - ANALYSIS OF CLINICAL AND PATHOLOGICAL FINDINGS IN 3 CASES [J].

KONDOH, Y ;

TANIGUCHI, H ;

KAWABATA, Y ;

YOKOI, T ;

SUZUKI, K ;

TAKAGI, K .

CHEST, 1993, 103 (06) :1808-1812

← 1 2 3 →